1 completed, 1 recruiting, 1 terminated, 1 withdrawn. 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
Follow Travera Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis Mass-based response testing (MRT) - Appendiceal Cancer, Colorectal Adenocarcinoma | Not applicable | Recruiting | Yale University | 20 | 2026-02-17 | 2026-07-21 |
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) Pleural Effusion, Malignant, Ascites, Malignant | Completed | Travera Inc | 72 | 2022-07-15 | 2026-04-13 | |
| Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma Multiple Myeloma in Relapse | Terminated | Travera Inc | 33 | 2019-02-11 | 2024-07-03 |
Appendiceal Neoplasms (3) · Anus Neoplasms (2) · Breast Neoplasms (2) · Carcinoma (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Neuroendocrine (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Cholangiocarcinoma (2) · Esophageal Neoplasms (2) · Laryngeal Neoplasms (2) · Lung Neoplasms (2) · Mesothelioma (2) · Mouth Neoplasms (2) · Neoplasms, Unknown Primary (2)
United States (3)
Cara Rosenbaum, M.D. (1) · Kiran Turaga, MD (1) · Mark Stevens, Ph.D. (1) · Mark Stevens, Phd (1) · Nikhil C Munshi, M.D. (1) · Rob Kimmerling, Phd (1) · Robert Kimmerling, Ph.D. (1)